Dr Reddy’s Laboratories has received US Food & Drug Administration (FDA) approval for Lansoprazole delayed-release capsules (15mg and 30mg), a bioequivalent generic version of Prevacid delayed-release capsules.
Subscribe to our email newsletter
Following the approval, the company expects to launch the drug in the US market, and it will commence the shipments shortly.
Lansoprazole delayed-release capsules are a combination package that contains a nonsteroidal anti-inflammatory drug (NSAID) and a proton pump inhibitor (PPI).
Dr Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30mg.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.